Q3 2023 Results - Reimagining Medicine

Company overview Financial review Conclusions Appendix References PluvictoⓇ grew to USD 256m; supply now unconstrained, focusing on initiating new patients Sales evolution USD m, % cc Ex-US US +217% 256 18 238 80 6 74 Q3 2022 Q3 2023 11 Investor Relations | Q3 2023 Results GROWTH P PLUVICTO™ Continued progress in Q3 ■ Growth rates slowed in the quarter given supply challenges earlier in the year ■ >200 active centers ordering in US and onboarding another approximately 130 ■ Ex-US reimbursement discussions ongoing Supply capacity now unconstrained; maintaining reliability ■ Millburn capacity expanded with FDA approval of two additional lines Indianapolis site submitted for FDA approval ☐ NOVARTIS | Reimagining Medicine

View entire presentation